CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Ascletis challenges psoriasis field with pill; Invivyd plans Covid filing

Neutral
AI Analysis

Summary

Ascletis is developing a small-molecule IL-17A inhibitor pill for psoriasis to compete with injectable therapies, while Invivyd plans to file a COVID-related product with regulatory authorities.

Importance:3/10
Sentiment:
0.00
psoriasissmall-moleculeIL-17A inhibitororal formulationCOVID-19
Related Companies

Read the original article

Published by Endpoints News on September 29, 2026 2:46 PM

Read Original